Last week the National Institute for Health and Care Excellence (NICE) decided not to recommend Xalkori for the treatment of ROS-positive non-small cell lung cancer in the United Kingdom. More information here: NICE Appraisal Consultation Document NICE shoots down Pfizer’s Xalkori in ROS1-positive patients, inviting a CDF proposal instead (from Fierce Biotech)
The European Society for Medical Oncology will hold their annual Congress in Madrid, Spain, on September 8-12 this year. The three presentations that will discuss ROS1 specifically are listed below (you can see the complete abstracts by clicking on the presentation title). 1308PD – Preliminary efficacy and safety of lorlatinib in patients (Pts) with ROS1-positive non-small … Continue reading #ROS1 Presentations at ESMO 2017
Tumor markers (certain molecules in the blood of cancer patients) can provide a useful “early warning” for cancer progression in patients whose lung cancer has alterations in ROS1, ALK, EGFR and KRAS genes. An analysis of data from 142 patients reviewed four tumor markers (CEA, CA125, CA19.9 and CA27.29) and found at least one tumor … Continue reading Tumor markers can help monitor ROS1, ALK, EGFR, and KRAS lung cancer patients
FOR IMMEDIATE RELEASE August 15, 2017 CONTACT: Samantha Cummis Addario Lung Cancer Medical Institute 650-598-2857 Samantha@LungCancerFoundation.org Susan Foreman Champions Oncology, Inc. 410-369-0365 SForeman@ChampionsOncology.com The Addario Lung Cancer Medical Institute, Champions Oncology and Motivated Patients Announce a Research Collaboration and Launch of a Patient Driven Clinical Study in ROS1 Positive Cancer SAN CARLOS, Calif. And Hackensack, … Continue reading Announcing a Research Collaboration and Launch of a Patient Driven Clinical Study in ROS1 Positive Cancer
A TP Therapeutics, Inc. drug designated TPX-0005 received FDA Orphan Drug Designation on June 27, 2017. The first patient enrolled in March 2017 in the TPX-0005 Phase 1 clinical trial for advanced solid tumors with ROS1, ALK, and NTRK rearrangements. Here is the clinical trial listing on clinicaltrials.gov: NCT03093116: A Study of TPX-0005 in Patients … Continue reading TPX-0005 (in trials for ROS1+ cancers) receives orphan drug designation
Crizotinib was approved last week for #ROS1-positive non-small cell lung cancer in Japan! I learned this from Dr Koichi Goto, Chief of Thoracic Oncology at the National Cancer Center Hospital East in Japan. I met him while wandering through the metastatic #lungcancer posters at #ASCO17.